PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
14.84%
D&A growth of 14.84% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
0.81%
SBC growth of 0.81% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
106.29%
Working capital of 106.29% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Growth of 81.80% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
No Data
No Data available this quarter, please select a different quarter.
9.51%
CFO growth of 9.51% while Biotechnology median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
38.16%
CapEx growth of 38.16% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
Investing flow of 38.16% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Issuance growth of 1171.17% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.